CosmoFarm Hits $60M Run-Rate with 80+ New Pharmacies, AI Automation

For the biotech and pharma industry, efficient drug distribution and scalable infrastructure are critical to commercial success. Cosmos Health's CosmoFarm subsidiary demonstrates how targeted automation and aggressive customer acquisition can propel a pharmaceutical wholesaler to a $60M+ run-rate, adding over 80 pharmacies in a single quarter.

Cosmos Health Inc. (NASDAQ:COSM) announced that its wholly owned subsidiary, CosmoFarm S.A., achieved a record $15+ million in revenue for Q2 2026, driving its annualized run-rate past $60 million. The pharmaceutical wholesaler, based in the greater Athens area, also expanded its distribution network by over 80 pharmacies during the period, underscoring robust demand and rapid market penetration. This performance highlights the success of CosmoFarm's automated distribution model and its growing role as a cornerstone of Cosmos Health's vertically integrated healthcare strategy.

“

(NASDAQ:COSM) announced that its wholly owned subsidiary, CosmoFarm S.A., achieved a record $15+ million in revenue for Q2 2026, driving its annualized run-rate past $60 million.

Cosmos Health, a diversified global healthcare group, relies on CosmoFarm to distribute its proprietary pharmaceutical and nutraceutical brands—including Sky Premium Life, Mediterranation, and bio-bebe—while also serving third-party pharma clients. The record quarterly figure, representing a more than doubling from prior periods, signals that the subsidiary is scaling effectively. The addition of 80+ new pharmacies in a single quarter is particularly notable in the fragmented Greek pharmacy market, where building trust and reliable delivery is critical. This customer growth not only increases revenue but also strengthens CosmoFarm's bargaining power with suppliers and its ability to cross-sell Cosmos Health's own branded products.

To sustain this momentum, Cosmos Health is investing in new robotic automation and artificial intelligence systems and expanding CosmoFarm's facility. These investments build upon the existing ROWA and SSI SCHÄFER A-frame robotic systems that have already enhanced operational efficiency and unit economics. The new AI-driven tools are expected to optimize procurement, inventory management, and order fulfillment, potentially improving gross margins in a business where thin profits are the norm. By leveraging predictive analytics, CosmoFarm can reduce waste, streamline stock rotation, and respond faster to pharmacy orders—a competitive advantage that could drive further market share gains.

From a strategic standpoint, the capital expenditure signals management's confidence in sustained growth, though the amounts were not disclosed. Investors should note that the $60 million annualized run-rate is based on a partial quarter's performance, which may not fully capture seasonality or variability. Additionally, as a press release, the forward-looking statements—such as margin improvements and scaling—carry execution risk. However, the underlying trend is clearly positive: CosmoFarm is expanding its footprint and modernizing its operations in a sector ripe for technological disruption.